BackIXICO plc Overview

IXICO plc EBIT

IXICO plc's EBIT is $-4.2M, below the Healthcare sector average of $1.9T.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$1.24M
↓ 33.93% YoY

As of Mar 31, 2026

Annual EBIT (TTM)

-$4.21M
↓ 89.87% YoY

Trailing 12 months ending Mar 31, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

IXICO plc (PHYOF) FAQ

The latest EBIT for PHYOF is $-4.2M as of March 2026. That compares with $-2.2M in the prior-year period — down 89.9% year over year. That is below the Healthcare sector average of $1.9T. Investors often review this figure alongside IXICO plc's historical trend and sector peers before judging valuation or financial health.

Over the past year, PHYOF's EBIT moved from $-2.2M to $-4.2M — a 89.9% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in IXICO plc's operating scale or balance-sheet position.

Against Healthcare companies, PHYOF currently prints $-4.2M for EBIT, while the sector average sits near $1.9T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at IXICO plc's growth, margins, and balance sheet.

A EBIT figure of $-4.2M for PHYOF is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.9T. Explore the charts below for those layers of context.

After noting PHYOF's EBIT ($-4.2M), review year-over-year change from $-2.2M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.